Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

By studying blood vessels at single cell resolution, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

3D rendered image of blood cells

The team has previously shown that development of myofibroblasts, the cells responsible for deposition of the excessive matrix and contraction, is dependent on production of tumour necrosis factor (TNF) by local immune cells. The research, published in PNAS showed that endothelial cells lining the blood vessels modulate the activity of immune regulatory fibroblasts, which secrete mediators that attract the immune cells. They also identified that a potential myofibroblast precursor cell that is contained within a compartment of cells called pericytes that wrap around the blood vessel wall.

First author on the paper, Dr Thomas Layton, who started the work as a Kennedy DPhil student at the Kennedy Institute of Rheumatology said: "This study illustrates the potential of using state of the art molecular biology techniques to relatively under studied diseases."

Read the full story on the NDORMS website

Similar stories

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.